Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Curently, Dr. Feld is clinician-scientist based at the Toronto Western Hospital Liver Clinic and the McLaughlin-Rotman Centre for Global Health.
Dr. Felds research focuses on understanding treatment non-response in hepatitis C and more broadly on understanding the antiviral immune response and developing new strategies for the treatment of viral hepatitis.
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Int J Drug Policy. 2018 Oct 29;62:94-103
What are the Benefits of a Sustained Virologic Response to Direct-acting Antiviral Therapy for HCV Infection?
Gastroenterology. 2018 Oct 24;:
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.
Int J Drug Policy. 2018 Oct 20;62:14-23
HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.
Lancet Gastroenterol Hepatol. 2018 Sep 28;:
Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.
PLoS One. 2018;13(8):e0201120
The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis.
Eur Radiol. 2018 Jul 26;:
Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework.
J Virus Erad. 2018 Jul 01;4(3):193-195
IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling.
Cytokine. 2018 Jun 13;:
N Engl J Med. 2018 Jun 14;378(24):2348-9
The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.
CMAJ. 2018 Jun 04;190(22):E677-E687
Scientist, Toronto General Hospital Research Institute (TGHRI)
Scientist, Sandra Rotman Centre for Global Health, Toronto, Ontario, Canada
Research Director, Gastroenterology, Medicine/University of Toronto, Francis Family Liver Clinic - Toronto Western Hospital, Toronto, Ontario, Canada
Associate Professor of Medicine, University of Toronto, Toronto, Ontario, Canada